Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 15/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16705677 | 0.94 | CXCR4 (0.61) | CXCR4MEN1KMT2ATDP1KDM5C | |
| SCHEMBL23780012 | 0.94 | CXCR4 (0.61) | CXCR4MEN1KMT2ATDP1KDM5C | |
| SCHEMBL17708319 | 0.92 | CXCR4 (0.58) | CXCR4MEN1KMT2ATDP1KDM5C | |
| SCHEMBL19013529 | 0.91 | CXCR4 (0.57) | CXCR4MEN1KMT2ATDP1KDM5C | |
| SCHEMBL16705602 | 0.88 | CXCR4 (0.56) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL31679420 | 0.88 | CXCR4 (0.56) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL16705603 | 0.88 | CXCR4 (0.56) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL24026607 | 0.85 | CXCR4 (0.52) | CXCR4MEN1KMT2ATDP1KDM5C | |
| SCHEMBL15159868 | 0.85 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL465886 | 0.85 | GNE (0.55) | CXCR4TDP1GNE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273142-A1 | PICOLINATE CYCLAM PALLADIUM CHELATES AND USES THEREOF | Université de Bretagne Occidentale (FR) | 2023-11-08 | — | — | EP | claimed |
| EP-4273142-A1 | PICOLINATE CYCLAM PALLADIUM CHELATES AND USES THEREOF | Université de Bretagne Occidentale (FR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273142-A1 | PICOLINATE CYCLAM PALLADIUM CHELATES AND USES THEREOF | Université de Bretagne Occidentale (FR) | 2023-11-08 | — | — | EP | disclosed |
| US-10434199-B2 | Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2019-10-08 | — | — | US | disclosed |
| EP-3068787-B1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-20160287733-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-10-06 | — | — | US | disclosed |
| US-20160287733-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-10-06 | — | — | US | disclosed |
| EP-2871186-B1 | Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015071334-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2015-05-21 | — | — | WO | disclosed |
| EP-2871186-A1 | Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof | Université de Bretagne Occidentale (FR) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434199-B2 | Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof | SLC39A14, SLC67A1, SLC39A3 | CXCR4 1254/4885MEN1 1087/4885CHRM2 113/4885 |
| US-20160287733-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | SLC39A14, SLC67A1, SLC39A3 | CXCR4 1254/4885MEN1 1087/4885CHRM2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.